文献速递妇产影像儿科影像技术与安全US

法国孕早期巨细胞病毒原发感染筛查与伐昔洛韦治疗策略的成本效果分析

Cost-effectiveness of screening and valacyclovir-based treatment strategies for first-trimester cytomegalovirus primary infection in pregnant women in France.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

该研究模拟法国每年80万妊娠人群,比较四种孕早期CMV原发感染筛查策略的成本与效果。结果显示,普遍筛查联合伐昔洛韦治疗(S4)较当前建议(S1)每避免一例先天性感染仅增加893欧元,且较当前实践(S2)更省钱;当前部分筛查实践(S2)被普遍筛查策略支配,成本效果不可接受。

要点

  • 普遍筛查联合伐昔洛韦治疗可经济有效地减少先天性CMV感染。
  • 法国当前部分筛查实践(S2)成本效果劣于普遍筛查,已不可接受。

核心结论

  • 在法国,当前孕早期CMV原发感染的部分筛查实践(S2)被普遍筛查策略支配,成本效果不可接受。
  • 普遍筛查联合伐昔洛韦治疗(S4)较当前建议(S1)具有成本效果,且较当前实践(S2)更节省成本。

研究设计与样本

  • 策略S1:不系统筛查(法国当前公共卫生建议);S2:筛查25-50%孕妇(法国当前筛查实践);S3:普遍筛查(法国当前医学建议);S4:普遍筛查联合孕早期原发感染时伐昔洛韦治疗。
  • 结局包括总成本、效果(先天性感染数、诊断感染数)和增量成本效果比(ICER)。

诊断标准与关键数值

  • 与S1相比,S3多诊断536例感染胎儿;S4避免375例先天性感染。
  • 第二分析中,S4较S1每避免一例先天性感染增加893欧元,且较S2节省成本。

临床应用与阅片要点

  • 支持在法国采用普遍筛查联合伐昔洛韦治疗策略以改善成本效果。
  • 当前部分筛查实践成本效果劣于普遍筛查,需重新评估筛查政策。

局限性

  • 研究为模拟模型,成本基于2022年法国数据,结果外推需谨慎。
  • 未报告模型结构、参数不确定性及敏感度分析细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the effectiveness, cost and cost-effectiveness of four screening strategies for first-trimester (T1) cytomegalovirus (CMV) primary infection (PI) in pregnant women in France.

METHODS: In a simulated pregnant population of 800 000 (approximate number of pregnancies each year in France), using costs based on the year 2022, we compared four CMV maternal screening strategies: Strategy S1, no systematic screening (current public health recommendations in France); Strategy S2, screening of 25-50% of the pregnant population (current screening practice in France); Strategy S3, universal screening (current medical recommendations in France); Strategy S4, universal screening (as in Strategy S3) in conjunction with valacyclovir in case of T1 PI. Outcomes were total cost, effectiveness (number of congenital infections, number of diagnosed infections) and incremental cost-effectiveness ratio (ICER). Two ICERs were calculated, comparing Strategies S1, S2 and S3 in terms of euros (€) per additional diagnosis, and comparing Strategies S1 and S4 in € per avoided congenital infection.

RESULTS: Compared with Strategy S1, Strategy S3 enabled diagnosis of 536 more infected fetuses and Strategy S4 prevented 375 congenital infections. Strategy S1 was the least expensive strategy (€98.3m total lifetime cost), followed by Strategy S4 (€98.6m), Strategy S2 (€106.0m) and Strategy S3 (€118.9m). In the first analysis, Strategy S2 was dominated and Strategy S3 led to an additional €38 552 per additional in-utero diagnosis, compared with Strategy S1. In the second analysis, Strategy S4 led to an additional €893 per avoided congenital infection compared with Strategy S1, and was cost-saving compared with Strategy S2.

CONCLUSIONS: In France, current screening practice for CMV PI during pregnancy is no longer acceptable in terms of cost-effectiveness because this strategy was dominated by universal screening. Moreover, universal screening in conjunction with valacyclovir treatment would be cost-effective compared with current recommendations and is cost-saving compared with current practice. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Périllaud-Dubois C, Hachicha-Maalej N, Lepers C, et al. Cost-effectiveness of screening and valacyclovir-based treatment strategies for first-trimester cytomegalovirus primary infection in pregnant women in France. Ultrasound Obstet Gynecol. 2023. PMID: 37099516. doi:10.1002/uog.26226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。